EpistemisSynthesis and Summary of Hematological Monitoring
To facilitate quick memorization and precision clinical decision-making, a general diagnostic monitoring map is presented for each pharmacological group analyzed.
File
| Pharmacological Group | Representative Drug | Main Monitoring Parameter | Specific Antidote / Reversal |
|---|---|---|---|
| Parenteral Anticoagulants | Unfractionated Heparin | PaTT (target 1.5 - 2.5 times control) / Anti-Xa | Protamine Sulfate |
| Low Molecular Weight Heparins | Enoxaparin Sodium | Non-systematic. Anti-Xa Activity in obese or pregnant women | Protamine Sulfate (partial reversal ~60%) |
| Vitamin K Antagonists | Warfarin / Acenocoumarol | INR (target 2.0 - 3.0 / 2.5 - 3.5 in mechanical valves) | Vitamin K1 (Phytomenadione) / Prothrombin Complex (4-F) |
| Thrombin Inhibitors (DOACs) | Dabigatran Etexylate | Non-systematic. Ecarina Time / Thrombin Time | Idarucizumab (*Praxbind*) |
| Factor Xa inhibitors (DOACs) | Rivaroxaban / Apixaban | Not systematic. Specific Calibrated Anti-Xa Assays | Andexanet Alfa (*Ondexxya*) |
| Thienopyridine Antiplatelets | Clopidogrel | Platelet function (VerifyNow) / Genotype CYP2C19 | Platelet transfusion (in case of imminent bleeding) |
| Synthetic Antifibrinolytics | Tranexamic Acid | Creatinine level and kidney function (strict dose adjustment) | There is no specific antidote |
| Hematopoietic Growth Factors | Filgrastim | Absolute Neutrophil Count (ANC) / Hemogram | Temporary suspension / Symptomatic support |
"Success in advanced hematological therapy consists of maintaining biological balance: enough power to avoid thrombosis, but the lowest dose to prevent bleeding."
Epistemis is educational review material. It is not a medical device, does not diagnose or prescribe treatment, and does not replace formal medical training, current clinical guidelines, or professional clinical judgment.
- System
- Hematology
- Cluster
- Integration and Advanced Review